Indivior updates on antitrust suits

Indivior – which was notified last week that 35 US states and the District of Columbia had filed a civil complaint alleging violations of state and federal antitrust and consumer protection laws – said the states released a redacted copy of this complaint yesterday.

This alleges, among other things, that Indivior, along with other defendants, switched SUBOXONE treatment from a tablet to a film formulation in order to prevent or delay the introduction of generic alternatives.

The company continues to take these allegations seriously, intends to defend this and other related actions, and will continue to cooperate with the relevant US government agencies in their investigations of the Company.

Story provided by